Mediven Receives CE Mark for Molecular, Rapid Immunoassay Tests

Jun 08, 2016

|

NEW YORK (GenomeWeb) – Medical Innovation Ventures (Mediven) has received the CE-IVD mark for molecular and rapid tests that facilitate diagnosis for fecal occult blood, pregnancy, dengue, and tuberculosis.

One of the rapid tests, the ProDetect FOB Rapid Test, is a direct binding immunoassay for rapidly and qualitatively detecting the presence of human occult blood in feces. The other rapid pregnancy tests detect the presence of hCG in urine during the early stages of pregnancy.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Free-Ish

Nebula Genomics is launching its genome sequencing service for free for people who provide certain information about themselves, the Boston Globe reports.

This Week in PLOS

In PLOS this week: grey wolf population genomics, mutations associated with lung adenocarcinoma survival, and more.

Isolation Worries

An opinion piece at Bloomberg discusses China's stance on genomic research.

Shaken Identity

Genetic ancestry testing can affect a person's sense of identity, the New York Times Magazine writes.

Main menu